Age-standardized death from<unk>  per 100,000 inhabitants in 2004 Worldwide,<unk>  is both the fourth-most common cause of cancer and deaths from cancer in women. In 2018, 570,000 cases of<unk>  were estimated to have occurred, with over 300,000 deaths. It is the second-most common cause of female-specific cancer after breast cancer, accounting for around 8% of both total cancer cases and total cancer deaths in women. About 80% of<unk> s occur in developing countries. It is the most frequently detected cancer during pregnancy, with an occurrence of 1.5 to 12 for every 100,000 pregnancies. Australia Australia had 734 cases of<unk>  in 2005. The number of women diagnosed with<unk>  has dropped on average by 4.5% each year since organised screening began in 1991 (1991–2005). Regular twice-yearly Pap tests can reduce the incidence of<unk>  up to 90% in Australia, and save 1,200 Australian women from dying from the disease each year. It is predicted that because of the success of the primary HPV testing programme there will be fewer than four new cases per 100 000 women annually by 2028. Canada In Canada, an estimated 1,300 women will have been diagnosed with<unk>  in 2008 and 380 will have died. India In India, the number of people with<unk>  is rising, but overall the age-adjusted rates are decreasing. Usage of condoms in the female population has improved the survival of women with cancers of the cervix. European Union In the European Union, about 34,000 new cases per year and over 16,000 deaths due to<unk>  occurred in 2004. United Kingdom<unk>  is the 12th-most common cancer in women in the UK (around 3,100 women were diagnosed with the disease in 2011), and accounts for 1% of cancer deaths (around 920 died in 2012). With a 42% reduction from 1988 to 1997, the NHS-implemented screening programme has been highly successful, screening the highest-risk age group (25–49 years) every 3 years, and those ages 50–64 every 5 years. United States An estimated 13,170 new<unk> s and 4,250<unk>  deaths will occur in the United States in 2019. The median age at diagnosis is 50. The rates of new cases in the United States was 7.3 per 100,000 women, based on rates from 2012 to 2016.<unk>  deaths decreased by approximately 74% in the last 50 years, largely due to widespread Pap test screening. The annual direct medical cost of<unk>  prevention and treatment prior to introduction of the HPV vaccine was estimated at $6 billion.
Cervical cancer
Vaginal cancer
Endometrial cancer
Uterine cancer
Ovarian cancer
Breast cancer
Ovarian disease
Breast disease